CTLA-4 and PD-1 Pathways
Explore this paper's citation graph
Summary
An overview of the CTLA-4 and PD-1 pathways and implications of their inhibition in cancer therapy is provided and the clinical profiles of immuno-oncology agents inhibiting these 2 checkpoints may vary based on their mechanistic differences.
- Type
- article
- Published
- 2016-02-01
- Cited by
- 2,114
- References
- 97
- OpenAlex
- https://openalex.org/W26558876
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:977661
Keywords
Geology
References
- PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
- Structural Analysis of CTLA-4 Function In Vivo1
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
- Reversal of the TCR Stop Signal by CTLA-4
- Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond
- Inhibitory B7-family molecules in the tumour microenvironment
- The immunobiology of cancer immunosurveillance and immunoediting.
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- The interaction properties of costimulatory molecules revisited.
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2.
- B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28
Cited by
- 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma
- Activation and Recruitment of Regulatory T Cells via Chemokine Receptor Activation in Trichinella spiralis-Infected Mice
- Prognostic significance of combined pretreatment lymphocyte counts and body mass index in patients with head and neck cancer treated with radiation therapy
- Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity
- Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
- Treg-associated monogenic autoimmune disorders and gut microbial dysbiosis
- The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
- Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer
- Immune based therapy for melanoma
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
- Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
- Molecular imaging of immunotherapy targets in cancer
- New therapeutic strategies for malignant pleural mesothelioma
- Poly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by increasing PD-L1 expression.
- Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.
- Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
- Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer.
- Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab
- Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Related papers
No related papers recorded.